Delamanid was safe and tolerable during a 6-month treatment period in patients with multidrug-resistant tuberculosis.
Risk for developing active tuberculosis has not been previously assessed in patients undergoing hematopoietic cell transplantation.
Introducing pyrazinamide molecular susceptibility testing in the treatment of multidrug-resistant tuberculosis improved outcomes without the use of new drugs and shortened the World Health Organization 20+ month regimen to 12 months.
A freeze-dried, temperature-stable, experimental tuberculosis vaccine candidate has entered a phase 1 human clinical trial.
A new vaccine candidate may stave off active TB in M tuberculosis-infected adults.
Patients with tuberculosis who had linezolid added to their treatment regimen did not have higher culture conversion rates compared with individuals who received standard treatment.
A deep-learning algorithm performed better than radiologists at detecting active pulmonary tuberculosis on chest radiographs.
Tuberculosis screening results may differ depending on blood draw methods.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
Patients with multi-drug resistant tuberculosis who were treated with bedaquiline in an optimized background regimen experienced high rates of successful treatment outcomes.
A transient resistance to rifampin may emerge in patients after taking rifaximin.
There may an increased risk for tuberculosis in patients with COPD within 3 years of inhaled corticosteroid use.
Regular psychosocial support may improve adherence to treatment in drug-resistant tuberculosis.
Within 6 months, 23% of patients with Mycobacterium avium complex lung disease who had received add-on amikacin liposome inhalation suspension had a culture conversion.
In patients with possible tuberculosis, sputum molecular testing may facilitate a more accurate and efficient assessment of disease.
Higher MIC in pretreatment M. tuberculosis isolates linked to relapse risk.
Rifampin had a significantly higher rate of treatment completion and fewer drug-related adverse events.
Both 15 mg and 20 mg rifampin doses showed a rapid decline in bacteria in patients with tuberculosis.
In 2017, a Work Group was assembled to conduct a systematic review of 3HP regimen studies published between January 2006 to June 2017, specifically looking at outcomes in children, individuals with HIV/AIDS, and those who self-administered treatment.
The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.
Control of active tuberculosis (TB) and a major effort to decrease latent TB infection are both necessary to reduce morbidity and achieve TB elimination in the United States.
Researchers developed an algorithmic approach to diagnosing lung cavitary diseases.
Bedaquiline and delamanid were effective and well tolerated in patients with multidrug-resistant tuberculosis.
Large cavitary lung disease may increase cough frequency that lasts for a longer duration in individuals with tuberculosis.
HIV-positive patients with pulmonary tuberculosis benefited from daily antituberculosis therapy in terms of effectiveness and rifampicin resistance.
Shorter treatment regimens for tuberculosis were associated with increased completion rates and fewer adverse events compared with traditional regimens.
Patients with type 2 diabetes treated with sulfonylureas had a higher risk of contracting tuberculosis compared with metformin.
New recommendations suggest that high risk tuberculosis patients with cough should be screened for pulmonary tuberculosis.
Recommendations for testing and treating latent TB infection have been discussed by a representative from the California Department of Public Health.
Self-administered TB therapy should be considered when directly observed therapy is not feasible.